What’s Going On With First Wave BioPharma Stock?

First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are trading higher Wednesday.  What To Know:

First Wave BioPharma, Inc. (NASDAQ:FWBI) shares are trading higher Wednesday. 

What To Know:

First Wave BioPharma then announced on Dec. 27 that it had entered into a non-binding agreement to sell its niclosamide program for the treatment of inflammatory bowel diseases to an undisclosed biopharmaceutical company in order to streamline its clinical pipeline.

The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to niclosamide, as well as future milestones and royalties. The transaction is expected to close in the first half of 2024.

The company announced on Dec. 18 that it will acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple late-stage clinical assets. The transaction is expected to close in the first half of 2024.

The company also recently effected a 1-for-20 reverse stock split of its outstanding shares of common stock.

Related News: Why NGM Biopharmaceuticals Stock Is Blasting Higher

FWBI Price Action: According to Benzinga Pro, First Wave BioPharma shares are up 48% at $5.67 at the time of publication.

Image: Myriams-Fotos from Pixabay

Total
0
Shares
Related Posts
Read More

Why Marin Software Stock Is Up

Marin Software announced the launch of its Anomaly Detector after the market close on Monday and said the tool, powered by OpenAI, automatically identifies and summarizes unexpected results in performance marketing campaigns across Google, Meta, Amazon, and other pay-per-click ad platforms.

MRIN

Read More

Psyched: Australia’s Innovative Program, Congressional Amendments, Therapy Reimbursement And More

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic stress disorder (PTSD) and psilocybin to combat treatment-resistant depression.

AWKNF